Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018174 · ClinicalTrials.gov registry record · Phase 3
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT00018174 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 247 participants.
The verdict
NCT00018174, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
Interventions
- DRUG Placebo
- DRUG Fluoxetine
- BEHAVIORAL Behavioral group smoking cessation treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 1998-02 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018174
The ClinicalTrials.gov registry entry for NCT00018174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00018174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018174 about?
NCT00018174 is a clinical study titled "Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers". This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to ra...
What is the current status of trial NCT00018174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 1998-02. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00018174?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG), Behavioral group smoking cessation treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00018174?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.